SELLAS Life Sciences (SLS) Asset Writedowns and Impairment (2015 - 2017)
SELLAS Life Sciences (SLS) reported Asset Writedowns and Impairment of -$3.6 million for Q4 2017, down 200.0% quarter-over-quarter from $3.6 million in Q3 2017.
SELLAS Life Sciences (SLS) Asset Writedowns and Impairment (2015 - 2017) Analysis & Trends
SELLAS Life Sciences (SLS) has 2 years of Asset Writedowns and Impairment data on file, last reported at -$3.6 million in Q4 2017.
- Asset Writedowns and Impairment for Q4 2017 came in at -$3.6 million, changed N/A year-over-year; the trailing twelve-month figure through Sep 2017 was $3.6 million (down 55.84% YoY), and the FY2021 annual result was $5.7 million, changed N/A from the prior year.
- Asset Writedowns and Impairment fell to -$3.6 million in Q4 2017 per SLS's latest filing, from $3.6 million in the prior quarter.
- Over five years, Asset Writedowns and Impairment peaked at $8.1 million in Q3 2015 and troughed at -$3.6 million in Q4 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 767,934.24 Bn | 767,934.20 Bn | - |
| 2 | Belite Bio | 55,234.00 Bn | 55,234.00 Bn | - |
| 3 | Quantum Biopharma | 17,823.14 Bn | 17,823.14 Bn | - |
| 4 | Legend Biotech | 3,624.50 Bn | 3,624.21 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,745.73 Bn | 1,745.73 Bn | - |
| 6 | Evaxion A | 1,540.85 Bn | 1,540.84 Bn | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - |
| 8 | Vertex Pharmaceuticals | 112.57 Bn | 105.33 Bn | 2.59 Bn |
| 9 | Abivax | 93.46 Bn | 93.46 Bn | - |
| 10 | SELLAS Life Sciences | 1.34 Bn | 1.34 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2017 | -3.56 Mn |
| Dec 31, 2017 | -3.56 Mn |
| Sep 30, 2017 | 3.56 Mn |
| Sep 30, 2017 | 3.56 Mn |
| Sep 30, 2015 | 8.07 Mn |
| Sep 30, 2015 | 8.07 Mn |